Eko announced yesterday that it appointed Bryan Humbarger as its new senior vice president of commercial with an emphasis on sales.
The digital health sales veteran’s new role includes responsibilities for overseeing sales and commercial operations for Eko’s AI and telemedicine software platforms for health systems, practices and providers worldwide, according to a news release.
“Eko’s next generation of cardiac and pulmonary solutions are already making a difference for providers and their patients, and I am thrilled to bring my experience in cardiology and digital health to further accelerate the adoption of Eko’s technology,” Humbarger said in the release. “Being at the forefront of delivering what’s next in cardiovascular care is my passion, and I am thrilled to continue this journey at Eko, a company making a difference in how cardiac and pulmonary care is delivered.”
Oakland, Calif.-based Eko welcomes Humbarger on the back of FDA clearance for its suite of algorithms that combine with the company’s digital stethoscopes to screen for heart conditions during routine physical exams in January. The company also received FDA emergency use authorization (EUA) for its ECG-based algorithm in May amid the COVID-19 pandemic.
Humbarger most recently held the position of VP of sales at cardiac digital health companies AliveCor and HeartFlow, having previously earned sales experience at medtech companies including Medtronic (NYSE:MDT) and Bioquell.
“Bryan’s leadership skills, proven ability to drive growth and passion for improving cardiac health will be key assets as Eko continues to expand adoption of our AI and telemedicine solutions,” Eko CEO & co-founder Connor Landgraf said. “Now more than ever, telemedicine is playing a critical role in caring for patients and Bryan will play a pivotal part in scaling operations for the company’s next phase of growth and continued expansion.”